Vivi Ann Florenes
Overview
Explore the profile of Vivi Ann Florenes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nyakas M, Fleten K, Haugen M, Engedal N, Sveen C, Farstad I, et al.
Sci Rep
. 2022 Mar;
12(1):5076.
PMID: 35332208
More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to...
2.
Dillard P, Koksal H, Maggadottir S, Winge-Main A, Pollmann S, Menard M, et al.
Mol Ther
. 2020 Nov;
29(3):1199-1213.
PMID: 33212301
T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for...
3.
Davidson B, McFadden E, Holth A, Brunetti M, Florenes V
Virchows Arch
. 2020 Jun;
477(6):857-864.
PMID: 32533344
The objective of this study was to analyze the expression and clinical role of mitosis regulators α-thalassemia/mental retardation syndrome X-linked (ATRX) and death-domain-associated protein (DAXX) in metastatic high-grade serous carcinoma...
4.
Flem-Karlsen K, Nyakas M, Farstad I, McFadden E, Wernhoff P, Jacobsen K, et al.
PLoS One
. 2020 Jan;
15(1):e0227187.
PMID: 31917795
Receptor tyrosine kinase AXL is a one-pass transmembrane protein upregulated in cancers and associated with lower survival and therapy resistance. AXL can be cleaved by the A Disintegrin and Metalloproteinases...
5.
Flem-Karlsen K, McFadden E, Omar N, Haugen M, Oy G, Ryder T, et al.
Mol Cancer Ther
. 2019 Dec;
19(3):895-905.
PMID: 31871265
Receptor tyrosine kinase AXL is found upregulated in various types of cancer, including melanoma, and correlates with an aggressive cancer phenotype, inducing cell proliferation and epithelial-to-mesenchymal transition. In addition, AXL...
6.
Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, et al.
Pigment Cell Melanoma Res
. 2019 Oct;
33(3):446-457.
PMID: 31660681
MX2 protein is a dynamin-like GTPase2 that has recently been identified as an interferon-induced restriction factor of HIV-1 and other primate lentiviruses. A single nucleotide polymorphism (SNP), rs45430, in an...
7.
Florenes V, Flem-Karlsen K, McFadden E, Bergheim I, Nygaard V, Nygard V, et al.
Transl Oncol
. 2019 May;
12(7):951-958.
PMID: 31096111
Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have...
8.
Karlsen K, McFadden E, Florenes V, Davidson B
Gynecol Oncol
. 2018 Nov;
152(2):408-415.
PMID: 30448261
Objective: The objective of this study was to analyze the expression level and clinical role of soluble AXL (sAXL) in cancers affecting the serosal surfaces, with focus on ovarian carcinoma....
9.
Davidson B, Bjornerem M, Holth A, Hellesylt E, Falkenthal T, Florenes V
Gynecol Oncol
. 2018 May;
150(1):136-142.
PMID: 29804637
Objective: To analyze the expression and clinical role of CHK1 and CHK2 in metastatic high-grade serous carcinoma (HGSC). Methods: HGSC effusions (n = 335; 280 peritoneal, 55 pleural) were analyzed...
10.
Ree A, Russnes H, Heinrich D, Dueland S, Boye K, Nygaard V, et al.
ESMO Open
. 2017 Aug;
2(2):e000158.
PMID: 28761742
Objective: Through the conduct of an individual-based intervention study, the main purpose of this project was to build and evaluate the required infrastructure that may enable routine practice of precision...